Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRC | P08575 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717552 | 0.82 | PTPRC (0.33) | PTPRC | |
| SCHEMBL5457240 | 0.78 | PIM1 (0.39) | PTPRC | |
| SCHEMBL783397 | 0.72 | — | — | |
| SCHEMBL18889482 | 0.70 | PTPRC (0.41) | PTPRCP4HBALOX5PTGS2 | |
| SCHEMBL18992911 | 0.68 | MAPT (0.41) | PTPRCP4HBALOX5PTGS2 | |
| SCHEMBL6345958 | 0.66 | PTPRC (0.74) | PTPRCP4HB | |
| SCHEMBL300031 | 0.58 | MAOA (0.37) | — | |
| P-Xyloquinone SCHEMBL49964 | 0.50 | PLK1 (0.60) | — | |
| SCHEMBL3624714 | 0.50 | ALDH1A1 (0.50) | — | |
| SCHEMBL57290 | 0.50 | MEN1 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977819-A | Organic electric energy transfer eutectic crystal with near infrared light thermal characteristics and preparation method of light heat storage fiber thereof | 苏州大学 | 2025-05-13 | — | — | CN | claimed |
| CN-115863651-B | In-situ coated high-voltage positive electrode material, preparation method and application thereof | 蜂巢能源科技股份有限公司 | 2024-10-18 | — | — | CN | claimed |
| CN-114113370-B | Analysis method of aromatic halogenated disinfection byproducts in water | 东南大学 | 2024-03-26 | — | — | CN | claimed |
| CN-116678983-A | Method for simultaneously determining halogenated benzoquinone substances in water by membrane solid phase extraction-liquid chromatography-mass spectrometry | 衢州市疾病预防控制中心 | 2023-09-01 | — | — | CN | claimed |
| CN-114113370-A | Analysis method of aromatic halogenated disinfection byproducts in water | 东南大学 | 2022-03-01 | — | — | CN | claimed |
| EP-1754514-A1 | Agent and method for colouring keratin fibres | Wella Aktiengesellschaft (DE) | 2007-02-21 | — | — | EP | claimed |
| US-20070000073-A1 | Agent and method for colouring keratin fibres | PROCTER & GAMBLE COMPANY, THE | 2007-01-04 | — | — | US | claimed |
| WO-2006094217-A2 | AGENT AND METHOD FOR COLOURING KERATIN FIBRES | THE PROCTER & GAMBLE COMPANY (US) | 2006-09-08 | — | — | WO | claimed |
| US-7070625-B2 | Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives | WELLA AG (DE) | 2006-07-04 | — | — | US | claimed |
| EP-0959881-B1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1448540-A1 | AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES | Wella Aktiengesellschaft (DE) | 2004-08-25 | — | — | EP | claimed |
| US-20040060124-A1 | Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives | HFC PRESTIGE INTERNATIONAL HOLDING SWITZERLAND S.A.R.L (CH) | 2004-04-01 | — | — | US | claimed |
| WO-2003042199-A1 | AGENT AND METHOD FOR COLORING KERATIN FIBERS CONTAINING 2-BENZOTHIAZOLINONE-HYDRAZONE AND QUINONE DERIVATIVES | WELLA AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | WO | claimed |
| US-20030060635-A1 | Methods of using bis-indolylquinones | TANG PENG C (US) | 2003-03-27 | — | — | US | claimed |
| EP-0959881-A4 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN INC (US) | 2001-06-27 | — | — | EP | claimed |
| EP-0959881-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | Sugen, Inc. (US) | 1999-12-01 | — | — | EP | claimed |
| US-5786488-A | DEHYDROBROMINATION OF A DIBROMOBENZOQUINONES WITH AT LEAST ONE INDOLES IN A POLAR SOLVENT AND A METAL CARBONATE TO FORM AN ANTITUMOR AGENT | SUGEN, INC. (US) | 1998-07-28 | — | — | US | claimed |
| WO-1998020874-A1 | SYNTHETIC METHODS FOR THE PREPARATION OF INDOLYLQUINONES AND MONO- AND BIS-INDOLYLQUINONES PREPARED THEREFROM | SUGEN, INC. (US) | 1998-05-22 | — | — | WO | claimed |
| EP-3841085-B1 | NBOME TEST | UNIV SYDNEY TECHNOLOGY (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-4360469-A | Preparation of quinones by salcomine-catalyzed oxidation of phenols | EASTMAN KODAK COMPANY (US) | 1982-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030060635-A1 | Methods of using bis-indolylquinones | IDO2, IDO1, IPO5 | PTPRC 3030/4885P4HB 3493/4885ALOX5 1013/4885 |
| US-20040060124-A1 | Agent and method for coloring keratin fibers containing 2-benzothiazolinone-hydrazone and quinone derivatives | KRT18, NDUFA1, NDUFA2 | PTPRC 2605/4885P4HB 424/4885ALOX5 4244/4885 |
| US-20070000073-A1 | Agent and method for colouring keratin fibres | KRT18, CDC73, OAT | PTPRC 1438/4885P4HB 181/4885ALOX5 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.